Organogenesis (NASDAQ:ORGO) Coverage Initiated by Analysts at Lake Street Capital

Lake Street Capital initiated coverage on shares of Organogenesis (NASDAQ:ORGO) in a report released on Friday morning, MarketBeat reports. The firm issued a buy rating and a $5.00 target price on the stock.

Separately, Cantor Fitzgerald restated an overweight rating and set a $5.00 price target on shares of Organogenesis in a research note on Friday, March 1st.

Organogenesis Trading Up 6.1 %

NASDAQ:ORGO opened at $2.80 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.41 and a current ratio of 2.74. The firm has a market cap of $371.20 million, a price-to-earnings ratio of 70.02 and a beta of 1.66. Organogenesis has a 52 week low of $1.96 and a 52 week high of $4.70. The firm has a 50-day moving average price of $2.63 and a two-hundred day moving average price of $3.12.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $109.98 million during the quarter, compared to analyst estimates of $100.44 million. Organogenesis had a net margin of 1.34% and a return on equity of 2.11%. During the same quarter last year, the business posted ($0.02) EPS. On average, equities analysts expect that Organogenesis will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Organogenesis

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in shares of Organogenesis by 94.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,663 shares of the company’s stock worth $27,000 after purchasing an additional 3,235 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Organogenesis in the 4th quarter valued at approximately $43,000. Palumbo Wealth Management LLC purchased a new position in Organogenesis in the 4th quarter valued at approximately $46,000. Barclays PLC grew its stake in Organogenesis by 80.6% in the 3rd quarter. Barclays PLC now owns 25,276 shares of the company’s stock valued at $80,000 after buying an additional 11,284 shares in the last quarter. Finally, Capital Square LLC grew its stake in Organogenesis by 23.8% in the 4th quarter. Capital Square LLC now owns 20,450 shares of the company’s stock valued at $84,000 after buying an additional 3,930 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.